Zusammenfassung
Introduction
Treating breast cancer patients every day leads to the development of a certain routine. Most women are in their 50s, hopefully they arrive early, and the impact of operation, chemotherapy, hormonal therapy, radiotherapy, and possibly trastuzumab is on our mind. Why bother about up-to-date standards of care when everything is clear? Do we need any further information except for those patients with unusual presentation? Often, we start to search the literature only when we are at our wits' end. And we find it a rather timeconsuming activity! Improving the quality of individual care for all patients is the main goal of the guidelines set by the German Gynaecological Oncology Working Group (Arbeitsgemeinschaft Gynäkolo-gische Onkologie, AGO). The idea is to give advice not only on rare cases but also for every-day patients. Individualised suggestions concerning diagnostics and treatment shall be guaranteed. Evidence-based decisions shall be the basis of all discussions with patients, relatives, and colleagues. Economic considerations have to be increasingly included in the decision making process. Guidelines can contribute to saving public resources. On the other hand, greater expenses can be justified to the health care provider if they are recommended in guidelines. Guidelines also improve the knowledge transfer from research to clinical practice. Furthermore, open questions are clearly outlined, thus giving directions for future clinical research. The AGO breast commission updated the AGO recommendations for diagnostics and therapy of breast cancer in January 2008 for the 7th time [1] . These wide-spread recommendations are arranged in 25 chapters of 10-15 slides each with brief and clear evidence-based statements. This year, special attention was given to the references. All topics were edited by members of the commission. The data bases evaluated were Pubmed, ASCO, SABCS, ECCO, EBCC, COCHRANE, among others. Publications of the last 5 years were screened systematically. In addition, the following existing guidelines were evaluated: St. Gallen Consensus for adjuvant therapy of breast cancer [2] , American Association of Clinical Oncology [3] , and National Comprehensive Cancer Network [4] . The AGO breast commission tries to provide the recommendations in an independent and transparent way. All topics were discussed in the plenum and agreed on; consensus or a predominant majority was aimed for. The authors of the chapters rotated nearly each year. The guidelines 2008 were presented to the public in January 2008 and discussed thoroughly. All conflicts of interest possibly resulting from co-operation and connections with the industry were disclosed. Members of the AGO commission are not only gynaecologists but also colleagues from the fields of radiology, pathology, radiotherapy and internal medicine. The requirements for a membership are clear, and all present members have to undergo the corresponding scoring process in regular intervals. Kantelhardt/Thomssen Evaluation of evidence was done using the Oxford Levels of Evidence (LoE) [5] . Additionally, the AGO committee members intentionally gave subjective clinically orientated recommendations to each individual guideline statement (table 1) . A detailed presentation of the guidelines as a text version appeared at the end of 2007 [6] . Being concisely up to date, the AGO recommendations have obtained their own relevance next to the S3 guideline 'Breast Cancer' of the German Cancer Society (Deutsche Krebsgesellschaft e. V.) [7] . Besides, they are an indispensable basis and preparation for the production of the S3 guideline. The most important new aspects of the AGO recommendations 2008 are presented in this report.
Important New Aspects of the AGO Recommendations 2008

Early Detection and Diagnosis
If clinical examination, mammography, and ultrasound are not conclusive, morphological diagnosis based on biopsy material is warranted, as magnetic resonance imaging (MRI) has a high sensitivity but too low a specificity to allow definitive diagnosis and is therefore not recommended for diagnosis (LoE 1c-A, AGO +/-). Minimally invasive biopsy allows definitive diagnosis in most cases at reduced expenditure.
Prognostic and Predictive Factors
Interesting results show the importance of metabolism for the effect of tamoxifen [9] . A polymorphism in the gene of the enzyme Cyp2D6 could therefore possibly predict this effect (LoE 2b-B, AGO+/-). Prognostic factors are especially important in node-negative breast cancer ( fig. 1 ). The use of computer-based software systems for estimation and visualisation of prognosis and therapeutic effects (e.g., adjuvantonline [8]) can be helpful (LoE 2b(-)-D, AGO+). Gene expression profiles such as Oncotype DX ® (Genomic Health, Inc., Redwood City, CA, USA) and Mammaprint ® (Agendia, Amsterdam, the Netherlands) show interesting results for prognosis and prediction. However, a validation of these results is still due. Therefore, these tests are not recommended for routine use (LoE 2b-B, AGO-). Participation in one of the current studies is recommended.
Adjuvant Endocrine Therapy in Premenopausal Patients
In low-risk situations, tamoxifen alone is considered standard therapy (LoE 1a-A, AGO++). The combination of gonadotropin-releasing hormone (GnRH) analogues plus tamoxifen can be discussed (LoE 1b-B, AGO+); therapy-induced morbidity, however, should then be considered (low risk!). Standard adjuvant chemo-endocrine therapy (in highand intermediate-risk situations) is the sequence of chemotherapy followed by 5 years of tamoxifen (LoE 1a-A, AGO++). In young patients (under 40 years), additional ovarian suppression can be useful (LoE 2a-C, AGO+), study participation is recommended.
Adjuvant Endocrine Therapy in Postmenopausal Patients
Tamoxifen for 5 years remains the unchanged 'good standard' (LoE 1a-A, AGO++). Most postmenopausal patients might nevertheless profit from an adjuvant therapy with aromatase inhibitors -either upfront or in sequence to tamoxifen (LoE1b-A, AGO++). Long-term data of the ATAC study [10] and the BIG study [11] show that primary aromatase inhibitor therapy and primary tamoxifen therapy can be considered as equal (AGO++). It has to be stated that, so far, there are no conclusive data in favour of either upfront therapy or sequential therapy with aromatase inhibitors ( fig. 2 ).
Adjuvant Chemotherapy and Trastuzumab Therapy
Anthracycline-based chemotherapy in triple combination (e.g. 5-fluorouracil, epirubicin, cyclophosphamide (FEC), 5-fluorouracil, doxorubicin, cyclophosphamide (FAC)) is regarded as standard chemotherapy. For node-positive tumours, additional use of taxane-containing regimens is recommended. Within taxane-containing regimens, FEC-docetaxel and docetaxel, doxorubucin, cyclosphosphamide are still clearly recommended (LoE 1b-B, AGO++). Further regimens are shown in figure 3 . Concerning survival, anthracycline-free therapy with docetaxel/cyclophos-phamide is superior to the combination therapy doxorubicin and cyclophosphamide (AC) and can be recommended in individual cases (LoE 1bB, AGO+). For node-positive breast cancer, the use of dose-dense (dd) chemotherapy is to be considered. Besides the AGO pattern dd(E-P-C) q2w, the American patterns dd(A-C-P) /dd(AC-P)
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in der DGGG e.V. sowie in der DKG e.V. q2w (both with G-CSF support) and AC-ddP q1w × 12 (LoE 1b-B, AGO+) are also applicable. Contributing to more clarification, it is separately mentioned that adjuvant trastuzumab therapy can be given at the same time with radiotherapy (LoE 2b-B, AGO+). The application of trastuzumab parallel to epirubicin must be limited to trials in the adjuvant and likewise in the metastatic situations (LoE 2b-B, AGO+/-).
Supportive Care
Dexrazoxane is recommended as antidote for anthracycline extravasations. Using anthracycline-containing therapy in patients with cardiac risk factors, dexrazoxane can be used for cardiac protection (LoE 2b-B, AGO+); however, alternative regimens (anthracycline-free therapy or administration of liposomal anthracycline) should be considered (LoE 5-D, AGO++). The use of anaemia prophylaxis by means of erythropoietin preparations does not improve prognosis. On the contrary, possible disadvantages must be taken into account. Primary prophylaxis for standard chemotherapy is therefore not indicated.
Therapy Side Effects
Risk factors for anthracycline-or trastuzumab-induced cardiotoxicitiy are age (> 65 years), obesity (body mass index > 27 kg/m 2 ), uncontrolled hypertension, hypercholesterolemia, diabetes mellitus, and pre-existing cardiac disease (including borderline left ventricular ejection fraction, LVEF). Radiotherapy of the chest wall is not considered as a risk factor any longer (LoE 2b-B).
Breast Cancer Surgery -Oncological Aspects
The surgical trauma should be minimised by sentinel lymph node procedures whenever possible. The diagnostic processing of the sentinel lymph node by means of reverse transcription polymerase chain reaction (RT-PCR) is not sufficiently validated and is not to be used (LoE 4-D, AGO-). Sentinel node excision (SNE) is not indicated in prophylactic bilateral or contralateral mastectomy (LoE 3b-B, AGO-/-). For perioperative staging for high metastatic potential, fluorodeoxyglucose-positron emission tomography (FDG-PET) or FDG-PET computed tomography (CT) are not recommended (LoE 2a-B, AGO-).
Plastic Reconstructive Aspects after Mastectomy
A large retrospective analysis of implant reconstruction [13] modifies the past rejection of using implants after radiotherapy of the chest wall. In principle, the implant supply is considered a possible method of reconstruction (LoE 2a-B; AGO+). Implant reconstruction without radiotherapy is very feasible (LoE 2a-B, AGO++). Due to current data, there is no longer a clear preference to the order of timing implant reconstruction and radiotherapy (implant supply before or after radiotherapy: LoE 2a-B, AGO+/-). Breast reconstruction by means of transrectus abdominis muscle (TRAM) flap is generally possible by pedicled or free techniques (LoE 3b-C, AGO+). When using free tissue transfer techniques, free TRAM, DIEP (deep inferior epigastric artery perforator) or SGAP (superior gluteal artery perforator) / IGAP (inferior gluteal artery perforator) flaps are recommended.
Adjuvant Radiotherapy
Radiotherapy of the locoregional lymph node areas has received special consideration for the first time. Irradiation of the supraclavicular region (supra clavicular groove (SCG) field) is recommend in the case of infestation of more than 9 axillary lymph nodes (LoE 3a-B, AGO++), involvement of level 3 lymph nodes (LoE 3b-B, AGO+), and insufficient axillary dissection (e.g., when only level 1 is dissected despite axillary lymph node involvement). Also, the SCG field should be included when the indication for axillary irradiation is given for other reasons. Irradiation of the internal mammary region is not recommended (LoE 4-D, AGO-). The indication for adjuvant radiotherapy after mastectomy is given regardless of systemic therapy (LoE 1a-A, AGO++). New data revealed that the indication for irradiation of the chest wall after mastectomy is likewise favourable when less than 4 axillary lymph nodes are involved. The absolute benefit might, however, be small in older patients (LoE 1a-A, AGO+).
Pathology
Emphasis is put on the standardisation of procedures, quality assurance, and central reviewing especially for HER2 testing. Discordant findings in core biopsy and open biopsy need a second opinion.
Breast Cancer Follow-Up
Unchanged clinical examination is advised as standard care during follow-up. Elaborate machine-aided diagnostics including PET or whole body MRI are not recommended (LoE 2b-B, AGO-).
Complementary Therapy and Hormonal Treatment
The main topic of this chapter is the treatment of postmenopausal symptoms such as hot flushes. When the patient is on tamoxifen, venlaflaxin (serotonin-norepinephrine reuptake inhibitor, SNRI) should be used as co-medication to minimise interference due to substances interacting with the tamoxifen metabolism (LoE 1b-B, AGO+). Paroxetine and fluoxetine could possibly lead to a loss of the tamoxifen effect. Apart from medical treatment, regular exercise can favourably affect postmenopausal hot flushes (LoE 2b-D, AGO+).
Precursor Lesions
The definition of lobular neoplasia (LN) was introduced in place of lobular carcinoma in situ (LCIS). Pleomorphic LCIS (LN 3) is emphasised as a special lesion which should be treated like ductal carcinoma in situ (DCIS). The treatment of LN has been re-arranged: i) LN in needle biopsy (core nee- 
Ductal Carcinoma Situ (DCIS)
Up to now, there have been no conclusive data to state in which cases radiotherapy after breast conserving therapy for DCIS can be omitted. All patients benefit, but no influence on survival is seen. Patients with low grade DCIS (< 2 cm, margins > 10 mm) may only have a minor benefit so that radiotherapy may be avoided. Breast conserving therapy can be offered in multifocal DCIS when operated with appropriate care, good imaging, and histopathologic examination (postoperative radiotherapy is presumed; LoE 2b-B; AGO+).
Hereditary Breast Cancer
The list of indications for testing for BRCA 1/2 mutation (probability ≥ 10%) was extended due to the data of the German consortium. When having male breast cancer in the family, a diagnostic procedure is only recommended if at least a second breast or ovarian cancer is found in the family (LoE 2b-B, AGO++). The discussion about giving chemotherapy with a platinum combination in BRCA 1/2-associated breast cancer is not finalised (LoE 3-C, AGO+/-). Study participation is recommended.
Breast Cancer in Specific Situations
Breast cancer in pregnancy should not justify preterm delivery (before maturation of the child), since this does not improve the prognosis (LoE 4-C, AGO++). The mode of delivery is not to be modified because of the breast cancer (LoE 4-C, AGO++), however, giving birth less than 3 weeks after the last chemotherapy should be avoided. When adjuvant chemotherapy is necessary after delivery, breast feeding may have to be stopped due to contraindications of the used substances. Pregnancy-associated breast cancer (diagnosis during and in the first year after pregnancy) should be entered into the national registry study of the German Breast Group. When treating elderly patients with breast cancer (> 70 years), geriatric assessments should always be taken into account (LoE 2b-B, AGO++). Fit elderly patients with good life expectancy (> 5 years), good physical condition, and little comorbidity can be offered therapy according to the usual standard (as in 'younger' patients) (LoE 2a-C, AGO++). Therapy for frail elderly patients must be adapted to the situation (LoE 2b-C, AGO++): reduced surgical therapy, reduced radiotherapy, no adjuvant chemotherapy. New recommendations concerning the treatment of sarcoma ( fig. 4) , inflammatory breast cancer ( fig. 5) , and Paget's disease of the breast were added. When suspecting Paget's disease of the breast, histological examination for suspicious nipple findings is obligatory, further diagnostics must exclude underlying invasive carcinoma or DCIS. The operation must always include the nipple and areola. When exclusively Paget's disease is found and operated with negative margins, no radiotherapy is required (LoE 4-D, AGO++).
Locoregional Recurrence
In the setting of operating locoregional recurrence with clini- 
Endocrine Therapy of Metastatic Breast Cancer
Since in particular the hormone receptor status can change during the course of the disease, it can be helpful to obtain a histology from metastatic sites (e.g., by needle biopsy).
Cytotoxic Therapy in Metastatic Breast Cancer
In addition to the known substances, nanoparticle-bound paclitaxel (nab paclitaxel) will be available in the future as an effective substance for first-line situations (also when pre-treated with anthracycline-based regimens) (LoE 2b-B, AGO+). When pre-treated with anthracyclines and taxanes, combinations of ixabepilone/capecitabine and gemcitabine/vinorelbin are also described as effective patterns. Due to the relatively high rate of neutropenia, these patterns should be used rather sparingly (LoE 2b-B, AGO+/-). Cytotoxic therapy in metastatic breast cancer can be continued as long as the 'therapeutic index' remains positive (advantages outweigh side effects). Therapy can be discontinued when reaching remission, or can be continuously given until progression (LoE 2b-B, AGO+).
In any case, one should not change therapy to alternative substances without progression (LoE 2b a -B, AGO-).
Specific Sites of Metastasis
When bone marrow is involved and associated with pancytopenia (marrow infiltration), a consistent, well controllable chemotherapy must be applied. Besides weekly epirubicin application, weekly paclitaxel administration can also be considered (LoE 5-D, AGO++).
Bone Metastases
The recommendations regarding the treatment of bone metastases remain unchanged in general. The special elaboration of the topic 'therapy-induced bone mineral loss' is new. The repeated measurement of the bone density appears nowadays recommendable, as soon as therapies with risks for bone mineral loss are started, e.g., aromatase inhibitors, GnRH analogues (LoE 2b-B, AGO+). Treatment with bisphosphonates is indicated in osteopenia or osteoporosis (LoE 1b-B, AGO+). Analogous to other situations (corticosteroid-induced osteoporosis), it can be concluded that regular exercise, calcium and vitamin D substitution, and adequate body weight (body mass index > 18 kg/m 2 ) can contribute to preventing further bone mineral loss (AGO++). Oestrogen therapy is not recommended, including hormone receptor-negative carcinoma (LoE 5-D, AGO-).
Targeted Treatment
Treatment with so-called 'targeted drugs' is granted a high significance in the future therapy of breast cancer. For lapatinib, a molecule which specifically inhibits the tyrosine kinase of epidermal growth factor receptor (EGFR) and HER2, data are available in metastatic breast cancer ( fig. 6 ). Patients pretreated with anthracyclines, taxanes, and trastuzumab, benefit from a combination of lapatinib and capecitabine (LoE 1b-B, AGO+). Therapy with trastuzumab and capecitabine is probably not sufficiently effective (LoE 2b-B, AGO+/-). There is insufficient experience for first-line therapy with lapatinib and paclitaxel in trastuzumab-naive patients (LoE 2b-B, AGO+/-). When resistant to radiotherapy, lapatinib can be helpful in combination with capecitabine for the treatment of brain metastases (LoE 2b-B, AGO+). Also, in the meantime, data have been published on bevacizumab, a monoclonal, human-© AGO e. V.
in der DGGG e.V. sowie in der DKG e.V. ised antibody against the angiogenetic vascular endothelial growth factor (VEGF) ( fig. 7) . In first-line therapy, the combination of paclitaxel and bevacizumab increases the rate of remission and extends the progression-free interval (LoE 1b-B, AGO+). Administering additional bevacizumab in second-line therapy (LoE 1b-B, AGO-) or in the combination with capecitabine (LoE 2b a B, AGO-) was not convincing.
Guidelines
